

Be Provisional!

Optimal Provisional Strategy for LM PCI

Hyeon-Cheol Gwon

**Heart Vascular Stroke Institute, Samsung Medical Center
Sungkyunkwan University School of Medicine**


Disclosure

- I have nothing to disclose related to this presentation.


Provisional approach in left main(LM) bifurcation

COBIS II registry
N=853, LM bifurcation

IRIS-MAIN registry
N=1,002, LM bifurcation



(a) Target-lesion failure




Song YB, JACC CVI 2014

Lee CH, CCI 2021


Provisional approach in left main(LM) bifurcation

- **EBC Main trial**

- N=467, Provisional vs. systematic 2-stent for LM bifurcation (Medina 1,1,1 or 0,1,1)
- SB stenting 22% in provisional group vs. 94% in systemic 2-stent group



Hildick-Smith D, Eur Heart J 2021






Arunothayaraj S, Eurointervention 2023


DK-crush is better than provisional approach?

- **DK-CRUSH V trial**

- N=482, DK-crush vs. provisional approach of LM bifurcation (Medina 1,1,1 or 0,1,1)



Clinical FU at 12 mo
Angiographic FU at 13 mo




EBC 16th guideline part II: Implanting two-stents

- **Stepwise layered provisional stenting** is recommended by the European Bifurcation Club as the preferred strategy to treat coronary bifurcation lesions, with the intention to keep the procedure as simple as possible and aiming to minimize the number of stents needed in a bifurcation lesion.
- Implantation of the first stent in the provisional stenting influences the next steps in the procedure if SB stenting (such as T-stenting, TAP or culotte techniques) is needed. It is recommended to **stent the most diseased branch first** when PS is used as an upfront 2-stent strategy.

When SB lesion is longer and more severe, SB-first elective 2-stenting technique may be preferred

- Bifurcation lesions treated with 2-stent techniques in COBIS II registry
- MV first (n=250) or SB first (n=423).




Subgroup	Patients	TLR (%) SB first	TLR (%) MV first	Favours SB first	Favours MV first	Hazard ratio (95% CI)	p-value	p for interaction
MV DS								0.04
≥70%	257	22/156 (14.1)	8/101 (7.9)			1.94 (0.86-4.36)	0.11	
<70%	416	30/267 (11.2)	23/149 (15.4)			0.71 (0.41-1.22)	0.22	
SB DS								0.27
≥70%	200	12/150 (8.0)	6/50 (12.0)			0.65 (0.24-1.73)	0.39	
<70%	472	40/273 (14.7)	25/199 (12.6)			1.20 (0.73-1.98)	0.47	
SB DS>MV DS								0.008
Yes	252	17/189 (9.0)	12/63 (19.0)			0.44 (0.21-0.92)	0.03	
No	420	35/234 (15.0)	19/186 (10.2)			1.54 (0.88-2.68)	0.13	
MV lesion length								0.01
≥18 mm	329	36/215 (16.7)	11/114 (9.7)			1.79 (0.91-3.53)	0.09	
<18 mm	344	16/208 (7.7)	20/136 (14.7)			0.53 (0.27-1.01)	0.05	
SB lesion length								0.15
≥7.5 mm	354	33/247 (13.4)	10/107 (9.4)			1.47 (0.72-2.98)	0.29	
<7.5 mm	319	19/176 (10.8)	21/143 (14.7)			0.73 (0.39-1.36)	0.32	

Stepwise layered provisional stenting

Role of proximal optimization technique (POT)


EBC strongly recommends POT as an essential part of stent optimization.

POT is more important in LM bifurcation, because the size discrepancy of PV and MB is a function of SB diameter, which is largest in this bifurcation.




Murray's law

$$D_{PV}^3 = D_{MB}^3 + D_{SB}^3$$



POT may be hemodynamically better than FKB




POT = proximal optimization technique
FKB = final kissing ballooning

The result of final kissing ballooning is quite variable





	Number Design	Primary endpoint	Outcomes	Results	Memo
Niemela M (NORDIC III) Circulation 2011	N=477 RCT	6-mo MACE	FKB 2.9%, non-FKB 2.9% P=NS	Neutral	
Gwon HC (COBIS I) Heart 2012	N=1,065 Registry	2-year MACE	FKB 9.5%, non-FKB 4.5% p=0.02	Worse	Higher MV TLR In FKB group
Yamawaki M Circ J 2014	N=253 Registry	3-year MACE	FKB 14.6% vs. non-FKB 6.9% p=0.07	Worse	Higher MV restenosis in FKB-group
Kim TH Int J Cardiol 2014	N=251 Registry	3-year MACE	FKB HR=0.40 (95% CI 0.19– 0.84), p=0.015	Better	ACS patients
Biondi-Zoccai G Heart Vessels 2014	N=2,813 Registry	2-year MACE	HR=1.01 (0.80–1.23) p=0.91	Neutral	
Gao Z Chin Med J 2015	N=790 Registry	4-year MACE	FKB: 7.8%, non-FKB 10.0% p=0.33	Neutral	Left main bifurcation
Kim YH (CROSS) JACC CVI 2015	N=306 RCT	1-year MACE	FKB 14.0%, non-FKB 11.6% p=0.57	Worse	Higher MV restenosis in FKB group
Yu CW (COBIS II) JACC CVI 2015	N=1,901 Registry	3-year MACE	HR=0.50 (95% CI: 0.30- 0.85), p = 0.01	Better	Lower MV TLR in FKB group
Lee CH (COBIS III) JACC Asia 2021	N=2,194 Registry	5-year TLF	SB open 6.7%, cross-over 7.0%, p=0.95	Neutral	Neutral in LM and true bifurcation

SB Strut Opening vs. Leave Alone

- N=2,194 patients treated with 1-stent strategy in COBIS III registry
- The long-term clinical outcome of the 1-stent strategy with simple crossover alone was comparable to those of additional SB-opening procedures.




EuroIntervention. 2018;13:e1785-e1793




SB Strut Opening vs. Leave Alone in LM and non-LM bifurcation

- N=2,194 patients treated with 1-stent strategy in COBIS III registry



Are you afraid of floating struts of SB ostium?


Stent thrombosis on the protruded stent






Images in Cardiovascular Intervention 2020

70 YO/M, Angina
SYNERGY™ to LAD/Diag bifurcation

Post PCI



18M FU




■ Full covered ■ Partially covered ■ Uncovered

*In 99 SBs (42 pts, 825 struts),
95.1% of floating struts were
fully covered after 12-month*

CROSS-COBIS trial underway in Korea


Comparing SB Stent Treatment or NOT after MV Stenting

CROSS COBIS



What is the indication to treat LCX os?



SMART-STRATEGY Trial



What is the indication to treat LCX os?

SMART-STRATEGY Trial

- N=258, bifurcation with a large SB
- SB stenting 13% in conservative, 36% in aggressive strategies




What is the indication to treat LCX os?

SMART-STRATEGY II Trial


- N=160, left main bifurcation
- LCX stenting 9.5% in conservative and 24% in aggressive group

Target lesion failure




No. at Risk	Time from randomization (month)				
	0	3	6	9	12
Conservative	101	98	98	95	89
Aggressive	105	104	100	97	93

Non-true bifurcation




True bifurcation



The indication of LCX treatment is better to be conservative.

How to treat this lesion?


LM bifurcation and 2 LAD-diagonal bifurcations




IVUS is crucial to determine the vessel size

How did I treat this lesion?

Tailored sequential POTs



3 bifurcations, 2 stents, 3 balloons, no kiss, 4 POTs



2.75X28 mm
12 atm

2.75X28 mm
18 atm
POT

3.5X32 mm
12 atm

3.5X32 mm
18 atm
POT

5.0X8 mm
14 atm
POT

3.5X32 mm
8 atm

5.0X8 mm
8 atm
POT

You may have noticed that I did not wire 2 diagonals.

Conclusion

- Stepwise layered provisional stenting is recommended as the preferred strategy to treat left main coronary bifurcation lesion.
- Proximal optimization technique is key to stent optimization.
- LCX os opening is not better than simple cross-over in 1-stent technique in term of long-term outcome.
- The indication of LCX treatment is better to be conservative.
- Bifurcation lesion may be the only lesion which is associated with a better outcome when treated conservatively.